Nanohale AG (FYB) | WebDisclosure

PRESS RELEASE

published on 02/17/2025 at 09:27, 2 months 12 days ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 2 months 12 days ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
BRIEF

published on 02/17/2025 at 08:10, 2 months 12 days ago

Formycon fait le point sur l'essai de phase III et les ajustements de valorisation

Formycon AG Stratégie De Commercialisation Essai De Phase III Commentaires De La FDA Évaluation Des Biosimilaires
PRESS RELEASE

published on 02/17/2025 at 08:05, 2 months 12 days ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts
BRIEF

published on 02/05/2025 at 06:35, 2 months 24 days ago

Lotus Pharmaceutical s'associe à Formycon pour commercialiser le biosimilaire Eylea® en Asie-Pacifique

Lotus Pharmaceutique Biosimilaire Eylea® Commercialisation En Asie-Pacifique Approbation De La FDA Et De L'UE Traitement Des Maladies De La Rétine
BRIEF

published on 02/05/2025 at 06:35, 2 months 24 days ago

Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical Eylea® Biosimilar Asia-Pacific Commercialization FDA And EU Approval Retinal Disease Treatment
PRESS RELEASE

published on 02/05/2025 at 06:30, 2 months 24 days ago

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region

Formycon AG Asia-Pacific Eylea Biosimilar FYB203/AHZANTIVE Lotus Pharmaceutical
BRIEF

published on 01/20/2025 at 06:35, 3 months 12 days ago

Formycon Secures EU Approval for Biosimilar FYB203

Formycon AG EU Approval Teva Pharmaceuticals Aflibercept Biosimilar FYB203
BRIEF

published on 01/20/2025 at 06:35, 3 months 12 days ago

Formycon obtient l'approbation de l'UE pour le biosimilaire FYB203

Formycon AG Teva Pharmaceuticals Aflibercept Homologation UE Biosimilaire FYB203
PRESS RELEASE

published on 01/20/2025 at 06:30, 3 months 12 days ago

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe

Biosimilar Formycon EU Approval AHZANTIVE Baiama

Published on 05/01/2025 at 08:00, 3 hours 37 minutes ago

Formation Metals Announces Appointment of Adrian Smith to Advisory Committee
Published on 05/01/2025 at 06:40, 4 hours 57 minutes ago

Cerrado Gold Announces Q4 And Annual 2024 Financial Results
Published on 05/01/2025 at 05:25, 6 hours 12 minutes ago

GLG Life Tech Corporation Reports 2024 Annual & Fourth Quarter Financial Results
Published on 05/01/2025 at 05:00, 6 hours 37 minutes ago

Alphinat Announces a Profit of $51,824 for Fiscal Year Ended August 31, 2024
Published on 05/01/2025 at 04:25, 7 hours 12 minutes ago

Alphinat Announces a Profit of $84,870 for Fiscal Year Ended August 31, 2023

View all ACCESSWIRE

Published on 05/01/2025 at 11:25, 12 minutes ago

Linde Reports First-Quarter 2025 Results (Earnings Release Tables Attached)
Published on 05/01/2025 at 10:26, 1 hour 11 minutes ago

Dalata Hotel Group PLC: TVR-Total Voting Rights
Published on 05/01/2025 at 10:00, 1 hour 37 minutes ago

El Salvador Leads Positive Crypto Regulation as Europe Drops - Coincub
Published on 05/01/2025 at 10:00, 1 hour 37 minutes ago

GBC AG confirms “Buy” rating for RedFish LongTerm Capital S.p.A. – Price target raised to €2.82
Published on 05/01/2025 at 09:05, 2 hours 32 minutes ago

2025 Q1 Interim Management Statement

View all EQS

Published on 04/30/2025 at 20:31, 15 hours 6 minutes ago

COMMUNIQUE DE PRESSE - RESULTATS 2024
Published on 04/30/2025 at 19:14, 16 hours 22 minutes ago

Report de la publication des résultats annuels 2024
Published on 04/30/2025 at 19:14, 16 hours 23 minutes ago

Solocal - Press Release - Filing of 2024 URD
Published on 04/30/2025 at 19:14, 16 hours 23 minutes ago

Solocal - Communiqué de presse - Mise à disposition du DEU 2024
Published on 04/30/2025 at 18:55, 16 hours 41 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 5, 2025

View all LES ECHOS COMFI WIRE

News